Print Page    Close Window

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


 0.36 (3.52%)

Market Cap$104,993,130

09/22/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $9.88 with a 52 week high of $21.59 and a 52 week low of $7.20.

Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development


Read More

Gemphire to Present at Cantor Fitzgerald Global Healthcare Conference on September 26 in New York


Read More

Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene


Read More

Gemphire Therapeutics, Inc. at Cantor Fitzgerald Global Healthcare Conference

09/26/17 8:00 a.m. ETView Event